Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8527 as HIV-1 Preexposure Prophylaxis in Women
NCT07071623Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of mk-8527 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with Adjudicated Human Immunodeficiency Virus Type 1 (HIV-1) Infection at 2 years, Number of Participants who Experience At Least One Adverse Event (AE) at 2 years and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07071623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07071623.